PECS I Block vs. Local Infiltration in Breast Augmentation Pain Management
Evaluating Preoperative PECS I Block and Intraoperative Local Anesthetic Infiltration for Postoperative Pain in Breast Augmentation: A Prospective, Double-Blind, Split-Body Study
1 other identifier
interventional
20
1 country
1
Brief Summary
This study aimed to compare the effectiveness of preoperative PECS I block and intraoperative local anesthetic infiltration in managing postoperative pain following breast augmentation surgery. The primary focus was to evaluate their impact on postoperative pain levels, perioperative remifentanil and postoperative opioid consumption and opioid-related side effects during the early recovery period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 3, 2024
CompletedFirst Submitted
Initial submission to the registry
December 3, 2024
CompletedFirst Posted
Study publicly available on registry
December 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 3, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 3, 2025
CompletedJuly 16, 2025
July 1, 2025
3 months
December 3, 2024
July 12, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postoperative Pain Intensity
The level of postoperative pain in each breast region (right vs. left) measured using the Numeric Rating Scale (NRS). Pain scores will be recorded at specific intervals: every 30 minutes for the first 2 hours, every 2 hours from 2 to 6 hours, at the 24th hour, on the 5th postoperative day, and at the 3rd month. The primary focus is the pain intensity within the first 6 hours postoperatively.
Up to 6 hours post-surgery.
Secondary Outcomes (4)
Opioid Consumption
Up to 24 hours post-surgery.
Opioid-Related Side Effects
Up to 24 hours post-surgery
Chronic Pain Assessment
At 3 months post-surgery
Postoperative Complications
Up to 3 months post-surgery
Study Arms (2)
PECS I Block Intervention Arm
EXPERIMENTALThis arm involves the application of a preoperative PECS I block with 10 mL of 0.5% bupivacaine under ultrasound guidance. The intervention targets the right breast, aiming to evaluate its effectiveness in managing postoperative pain compared to local anesthetic infiltration.
Local Anesthetic Infiltration Intervention Arm
EXPERIMENTALThis arm involves the administration of intraoperative local anesthetic infiltration using 10 mL of 0.5% bupivacaine under direct visualization. The intervention targets the left breast, aiming to compare its effectiveness in managing postoperative pain against the PECS I block.
Interventions
The PECS I block is a regional anesthesia technique performed preoperatively under ultrasound guidance. It involves the injection of 10 mL of 0.5% bupivacaine between the pectoralis major and pectoralis minor muscles to block the medial and lateral pectoral nerves. This procedure targets the right breast in the study to reduce postoperative pain and is compared to local anesthetic infiltration.
Local anesthetic infiltration involves the intraoperative administration of 10 mL of 0.5% bupivacaine under direct visualization into the pectoralis major muscle prior to muscle transection. This procedure targets the left breast in the study for pain management and is compared to the PECS I block.
Eligibility Criteria
You may qualify if:
- Female participants aged 18 to 59 years.
- ASA (American Society of Anesthesiologists) physical status I or II.
- Scheduled for primary breast augmentation surgery using a dual-plane or submuscular approach.
- Planned to receive silicone implants of identical volume and shape for both breasts.
- Able to provide written informed consent.
- Willing and able to comply with study procedures and follow-up assessments.
You may not qualify if:
- Planned subglandular or subfascial breast augmentation.
- Undergoing revision breast surgery.
- History of breast disease, previous breast or axillary surgery, or breast cancer.
- Preoperative breast pain or chronic pain syndromes (e.g., fibromyalgia, chronic headaches, back pain, complex regional pain syndrome, neuropathic pain, osteoarthritis, or radicular pain).
- BIRADS score \> 3 based on imaging (ultrasound/mammography) within the past year.
- Allergy to medications used in the study (e.g., bupivacaine, propofol, fentanyl, sevoflurane, cefazolin, paracetamol, ondansetron, tramadol, or morphine HCl).
- Coagulopathy or bleeding disorders.
- Pregnant or at risk of pregnancy.
- Inability to provide informed consent or communication difficulties.
- Significant medical conditions that may interfere with the study outcomes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Yeditepe University Kozyatagi Hospital
Istanbul, Atasehir, 34752, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mert Ersan, Asst.Prof.
Yeditepe University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Asst. Prof.
Study Record Dates
First Submitted
December 3, 2024
First Posted
December 6, 2024
Study Start
October 3, 2024
Primary Completion
January 3, 2025
Study Completion
February 3, 2025
Last Updated
July 16, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- The data and supporting information will be made available after the study is completed, analyzed, and the results are published in a peer-reviewed journal. IPD and supporting documents will be shared through a secure online repository or data-sharing platform, accessible only to approved researchers
- Access Criteria
- Researchers must submit a formal data-sharing request, including a detailed explanation of how the data will be used. A data-sharing agreement must be signed to ensure the ethical use of the shared information, adherence to confidentiality, and compliance with relevant regulations.
The following specific individual participant data (IPD) will be shared: De-identified Participant Data: Demographic data (age, BMI, ASA classification). Pain scores measured using the Numeric Rating Scale (NRS) at predefined intervals. Postoperative opioid consumption (tramadol and morphine requirements). Incidence of postoperative complications (e.g., sensory changes, wound dehiscence). Data Dictionary: A comprehensive guide explaining the variables and coding used in the dataset to ensure accurate interpretation by other researchers. Exclusions: Personally identifiable information (e.g., names, contact information) will not be shared to maintain participant confidentiality. The data will be shared after the study is completed, analyzed, and the results are published in a peer-reviewed journal. Access will be granted only to researchers who provide a justified request and agree to the terms of a formal data-sharing agreement